Limits...
The relationship between clinicopathological features and expression of epithelial and mesenchymal markers in spontaneous canine mammary gland tumors.

Yoshida K, Yoshida S, Choisunirachon N, Saito T, Matsumoto K, Saeki K, Mochizuki M, Nishimura R, Sasaki N, Nakagawa T - J. Vet. Med. Sci. (2014)

Bottom Line: Consequently, loss of ZO-1 and E-cadherin, and gain of vimentin and N-cadherin were more frequently observed in malignant tumors than in benign tumors.However, there was no correlation among expression of these molecules.Univariate and multivariate analysis identified that loss of E-cadherin independently had a low one-year survival rate (adjusted odds ratio: 2.3, P=0.02).

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.

ABSTRACT
It is known that epithelial mesenchymal transition (EMT) contributes to the acquisition of malignant property in human cancers. However, the role of EMT in canine tumors remains to be elucidated. To evaluate the correlation between expression levels of protein markers involved in EMT and clinicopathological characteristics in canine mammary gland tumors, immunohistochemistry using antibodies against ZO-1, E-cadherin, vimentin, N-cadherin and fibronectin was performed on 119 clinical tissue samples. Consequently, loss of ZO-1 and E-cadherin, and gain of vimentin and N-cadherin were more frequently observed in malignant tumors than in benign tumors. However, there was no correlation among expression of these molecules. Univariate and multivariate analysis identified that loss of E-cadherin independently had a low one-year survival rate (adjusted odds ratio: 2.3, P=0.02). These results suggested that EMT might relate to acquisition of malignancy, and additionally, E-cadherin was strongly correlated with malignant behavior in canine mammary gland tumors.

Show MeSH

Related in: MedlinePlus

Representative findings of immunohistochemistry with antibodies against epithelialmarkers ZO-1 and E-cadherin. (A) Strong expression of ZO-1 was observed in tumorcells. (B) ZO-1 was weakly expressed in tumor cells (arrowheads). (C) E-cadherin wasstrongly expressed in tumor cells. (D) E-cadherin was weakly expressed in tumor cells(arrows). Occasionally, disappearance of E-cadherin was observed (arrowhead).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4221164&req=5

fig_001: Representative findings of immunohistochemistry with antibodies against epithelialmarkers ZO-1 and E-cadherin. (A) Strong expression of ZO-1 was observed in tumorcells. (B) ZO-1 was weakly expressed in tumor cells (arrowheads). (C) E-cadherin wasstrongly expressed in tumor cells. (D) E-cadherin was weakly expressed in tumor cells(arrows). Occasionally, disappearance of E-cadherin was observed (arrowhead).

Mentions: Expression of epithelial markers: Expressions of ZO-1 and E-cadherin wereobserved on the cell membrane and/or cytoplasm (Fig.1Fig. 1.


The relationship between clinicopathological features and expression of epithelial and mesenchymal markers in spontaneous canine mammary gland tumors.

Yoshida K, Yoshida S, Choisunirachon N, Saito T, Matsumoto K, Saeki K, Mochizuki M, Nishimura R, Sasaki N, Nakagawa T - J. Vet. Med. Sci. (2014)

Representative findings of immunohistochemistry with antibodies against epithelialmarkers ZO-1 and E-cadherin. (A) Strong expression of ZO-1 was observed in tumorcells. (B) ZO-1 was weakly expressed in tumor cells (arrowheads). (C) E-cadherin wasstrongly expressed in tumor cells. (D) E-cadherin was weakly expressed in tumor cells(arrows). Occasionally, disappearance of E-cadherin was observed (arrowhead).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4221164&req=5

fig_001: Representative findings of immunohistochemistry with antibodies against epithelialmarkers ZO-1 and E-cadherin. (A) Strong expression of ZO-1 was observed in tumorcells. (B) ZO-1 was weakly expressed in tumor cells (arrowheads). (C) E-cadherin wasstrongly expressed in tumor cells. (D) E-cadherin was weakly expressed in tumor cells(arrows). Occasionally, disappearance of E-cadherin was observed (arrowhead).
Mentions: Expression of epithelial markers: Expressions of ZO-1 and E-cadherin wereobserved on the cell membrane and/or cytoplasm (Fig.1Fig. 1.

Bottom Line: Consequently, loss of ZO-1 and E-cadherin, and gain of vimentin and N-cadherin were more frequently observed in malignant tumors than in benign tumors.However, there was no correlation among expression of these molecules.Univariate and multivariate analysis identified that loss of E-cadherin independently had a low one-year survival rate (adjusted odds ratio: 2.3, P=0.02).

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.

ABSTRACT
It is known that epithelial mesenchymal transition (EMT) contributes to the acquisition of malignant property in human cancers. However, the role of EMT in canine tumors remains to be elucidated. To evaluate the correlation between expression levels of protein markers involved in EMT and clinicopathological characteristics in canine mammary gland tumors, immunohistochemistry using antibodies against ZO-1, E-cadherin, vimentin, N-cadherin and fibronectin was performed on 119 clinical tissue samples. Consequently, loss of ZO-1 and E-cadherin, and gain of vimentin and N-cadherin were more frequently observed in malignant tumors than in benign tumors. However, there was no correlation among expression of these molecules. Univariate and multivariate analysis identified that loss of E-cadherin independently had a low one-year survival rate (adjusted odds ratio: 2.3, P=0.02). These results suggested that EMT might relate to acquisition of malignancy, and additionally, E-cadherin was strongly correlated with malignant behavior in canine mammary gland tumors.

Show MeSH
Related in: MedlinePlus